FDA Approved: ALOGLIPTIN AND PIOGLITAZONE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)

View source ↗

Summary

The FDA approved a supplemental application for the fixed-dose combination of alogliptin benzoate and pioglitazone from Padagis Israel Pharmaceuticals Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Alogliptin and pioglitazone (Alogliptin benzoate and pioglitazone hydrochloride)

Snippet

SUPPL AP for ALOGLIPTIN AND PIOGLITAZONE (ALOGLIPTIN BENZOATE AND PIOGLITAZONE HYDROCHLORIDE)